Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer

计划入组 63 人 · 首次发布于 2018 年 8 月 8 日

Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

计划入组 30 人 · 首次发布于 2021 年 5 月 11 日

KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer

计划入组 22 人 · 首次发布于 2019 年 2 月 20 日

Rona Therapeutics Reports 99% Lipoprotein(a) Reduction with Annual-Dose RNAi Therapy RN026

KN026 Plus Docetaxel Shows Promise in HER2+ Metastatic Breast Cancer

Alphamab Oncology's KN026 Receives Breakthrough Therapy Designation for HER2-Positive Gastric Cancer in China